Panelists discuss how adjuvant therapy in HR+/HER2- early-stage breast cancer is influenced by key risk factors, with a focus on recent studies involving CDK4/6 inhibitors like abemaciclib, ribociclib, and palbociclib, and how these treatments are shaping the adjuvant treatment strategy based on efficacy data from trials such as MonarchE, NATALEE, and PALLAS.
Source :
For further details, visit: https://www.onclive.com/view/cdk4-6-inhibitors-for-hr-her2–early-breast-cancer
